Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma.
Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Perilongo G, et al. Among authors: de camargo b. N Engl J Med. 2009 Oct 22;361(17):1662-70. doi: 10.1056/NEJMoa0810613. N Engl J Med. 2009. PMID: 19846851 Free article. Clinical Trial.
Hepatoblastoma presenting with lung metastases: treatment results of the first cooperative, prospective study of the International Society of Paediatric Oncology on childhood liver tumors.
Perilongo G, Brown J, Shafford E, Brock P, De Camargo B, Keeling JW, Vos A, Philips A, Pritchard J, Plaschkes J. Perilongo G, et al. Among authors: de camargo b. Cancer. 2000 Oct 15;89(8):1845-53. doi: 10.1002/1097-0142(20001015)89:8<1845::aid-cncr27>3.0.co;2-d. Cancer. 2000. PMID: 11042582 Clinical Trial.
Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study.
Zsíros J, Maibach R, Shafford E, Brugieres L, Brock P, Czauderna P, Roebuck D, Childs M, Zimmermann A, Laithier V, Otte JB, de Camargo B, MacKinlay G, Scopinaro M, Aronson D, Plaschkes J, Perilongo G. Zsíros J, et al. Among authors: de camargo b. J Clin Oncol. 2010 May 20;28(15):2584-90. doi: 10.1200/JCO.2009.22.4857. Epub 2010 Apr 20. J Clin Oncol. 2010. PMID: 20406943 Clinical Trial.
Prognostic stratification for children with hepatoblastoma: the SIOPEL experience.
Maibach R, Roebuck D, Brugieres L, Capra M, Brock P, Dall'Igna P, Otte JB, De Camargo B, Zsiros J, Zimmermann A, Aronson D, Childs M, Scopinaro M, Morland B, Plaschkes J, Czauderna P, Perilongo G. Maibach R, et al. Among authors: de camargo b. Eur J Cancer. 2012 Jul;48(10):1543-9. doi: 10.1016/j.ejca.2011.12.011. Epub 2012 Jan 13. Eur J Cancer. 2012. PMID: 22244829 Clinical Trial.
Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma--a phase II trial of the childhood liver tumour strategy group (SIOPEL).
Zsíros J, Brugières L, Brock P, Roebuck D, Maibach R, Child M, Morland B, Casanova M, Pariente D, Paris C, de Camargo B, Ronghe M, Zimmermann A, Plaschkes J, Czauderna P, Perilongo G. Zsíros J, et al. Among authors: de camargo b. Eur J Cancer. 2012 Dec;48(18):3456-64. doi: 10.1016/j.ejca.2012.06.023. Epub 2012 Jul 24. Eur J Cancer. 2012. PMID: 22835780 Clinical Trial.
Clear cell sarcomas of the kidney registered on International Society of Pediatric Oncology (SIOP) 93-01 and SIOP 2001 protocols: a report of the SIOP Renal Tumour Study Group.
Furtwängler R, Gooskens SL, van Tinteren H, de Kraker J, Schleiermacher G, Bergeron C, de Camargo B, Acha T, Godzinski J, Sandstedt B, Leuschner I, Vujanic GM, Pieters R, Graf N, van den Heuvel-Eibrink MM. Furtwängler R, et al. Among authors: de camargo b, de kraker j. Eur J Cancer. 2013 Nov;49(16):3497-506. doi: 10.1016/j.ejca.2013.06.036. Epub 2013 Jul 20. Eur J Cancer. 2013. PMID: 23880476
Hepatocellular Carcinoma in Children: Does Modified Platinum- and Doxorubicin-Based Chemotherapy Increase Tumor Resectability and Change Outcome? Lessons Learned From the SIOPEL 2 and 3 Studies.
Murawski M, Weeda VB, Maibach R, Morland B, Roebuck DJ, Zimmerman A, Casanova M, Perilongo G, Laithier V, Kebudi R, Scopinaro MJ, Shun A, Brichard B, de Camargo B, Childs M, Aronson DC, Czauderna P. Murawski M, et al. Among authors: de camargo b. J Clin Oncol. 2016 Apr 1;34(10):1050-6. doi: 10.1200/JCO.2014.60.2250. Epub 2016 Jan 25. J Clin Oncol. 2016. PMID: 26811523
Use of amifostine in the therapy of osteosarcoma in children and adolescents.
Petrilli AS, Oliveira DT, Ginani VC, Kechichian R, Dishtchekenian A, Filho Wde M, Tanaka C, Dias CG, Latorre Mdo R, Brunetto AL, Cardoso H, Almeida MT, de Camargo B. Petrilli AS, et al. Among authors: de camargo b. J Pediatr Hematol Oncol. 2002 Mar-Apr;24(3):188-91. doi: 10.1097/00043426-200203000-00006. J Pediatr Hematol Oncol. 2002. PMID: 11990304 Clinical Trial.
Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: a report of the SIOP renal tumour study group.
van den Heuvel-Eibrink MM, van Tinteren H, Rehorst H, Coulombe A, Patte C, de Camargo B, de Kraker J, Leuschner I, Lugtenberg R, Pritchard-Jones K, Sandstedt B, Spreafico F, Graf N, Vujanic GM. van den Heuvel-Eibrink MM, et al. Among authors: de camargo b, de kraker j. Pediatr Blood Cancer. 2011 May;56(5):733-7. doi: 10.1002/pbc.22922. Epub 2010 Dec 22. Pediatr Blood Cancer. 2011. PMID: 21370404
Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial.
Pritchard-Jones K, Bergeron C, de Camargo B, van den Heuvel-Eibrink MM, Acha T, Godzinski J, Oldenburger F, Boccon-Gibod L, Leuschner I, Vujanic G, Sandstedt B, de Kraker J, van Tinteren H, Graf N; SIOP Renal Tumours Study Group. Pritchard-Jones K, et al. Among authors: de camargo b, de kraker j. Lancet. 2015 Sep 19;386(9999):1156-64. doi: 10.1016/S0140-6736(14)62395-3. Epub 2015 Jul 9. Lancet. 2015. PMID: 26164096 Free article. Clinical Trial.
166 results